Risk of myocardial infarction and nucleoside analogues

The Lancet

Volumn 371, Issue 9622, 2008, Pages 1391-1392

  Stein, James H ^a   Currier, Judith S ^b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIVIRUS AGENT; DIDANOSINE; LAMIVUDINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ANGINA PECTORIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; FOLLOW UP; HEART INFARCTION; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SUDDEN DEATH; THROMBOSIS; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS;

EID: 42649110658     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60491-2     Document Type: Note

References (9)